Search research articles
Contact Us
Filters
Showing results (51-60 of 224) with videos related to
Page
of 23
Sort By:
Hemasphere
|
August 18, 2020
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
Davide Rossi, Mazyar Shadman, Adalgisa Condoluci, et al.
Ejhaem
|
December 18, 2024
A phase 2 study of frontline pembrolizumab in follicular lymphoma
Carrie Ho, Songli Zhu, Ted Gooley, et al.
Transfusion
|
May 9, 2012
Transfusion-associated graft-versus-host disease in a liver transplant recipient: an unusual presentation and review of the literature
Kerry L O'Brien, Shalini E Pereira, Jeffrey Wagner, et al.
Nutrition and Cancer
|
May 21, 2011
Colorectal polyp type and the association with charred meat consumption, smoking, and microsomal epoxide hydrolase polymorphisms
Andrea N Burnett-Hartman, Polly A Newcomb, Margaret T Mandelson, et al.
Haematologica
|
July 3, 2025
Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Alexey V Danilov, Hongli Li, Mazyar Shadman, et al.
Blood Advances
|
April 9, 2025
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis
Mazyar Shadman, Jennifer R Brown, Leyla Mohseninejad, et al.
Blood Advances
|
January 26, 2026
An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL
Mazyar Shadman, Constantine S Tam, Danielle M Brander, et al.
American Journal of Hematology
|
May 2, 2020
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts
Brian Koffman, Anthony Mato, John C Byrd, et al.
Current Medical Research and Opinion
|
September 27, 2023
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab
Paolo Ghia, Gisoo Barnes, Keri Yang, et al.
Transplantation and Cellular Therapy
|
October 25, 2025
Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers
Mazyar Shadman, Sairah Ahmed, Michael T Byrne, et al.
Page
of 23
Search research articles
Search
Showing results (51-60 of 224) with videos related to
Sort By:
Page
of 23
Hemasphere
|
August 18, 2020
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
Davide Rossi, Mazyar Shadman, Adalgisa Condoluci, et al.
Ejhaem
|
December 18, 2024
A phase 2 study of frontline pembrolizumab in follicular lymphoma
Carrie Ho, Songli Zhu, Ted Gooley, et al.
Transfusion
|
May 9, 2012
Transfusion-associated graft-versus-host disease in a liver transplant recipient: an unusual presentation and review of the literature
Kerry L O'Brien, Shalini E Pereira, Jeffrey Wagner, et al.
Nutrition and Cancer
|
May 21, 2011
Colorectal polyp type and the association with charred meat consumption, smoking, and microsomal epoxide hydrolase polymorphisms
Andrea N Burnett-Hartman, Polly A Newcomb, Margaret T Mandelson, et al.
Haematologica
|
July 3, 2025
Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Alexey V Danilov, Hongli Li, Mazyar Shadman, et al.
Blood Advances
|
April 9, 2025
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis
Mazyar Shadman, Jennifer R Brown, Leyla Mohseninejad, et al.
Blood Advances
|
January 26, 2026
An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL
Mazyar Shadman, Constantine S Tam, Danielle M Brander, et al.
American Journal of Hematology
|
May 2, 2020
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts
Brian Koffman, Anthony Mato, John C Byrd, et al.
Current Medical Research and Opinion
|
September 27, 2023
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab
Paolo Ghia, Gisoo Barnes, Keri Yang, et al.
Transplantation and Cellular Therapy
|
October 25, 2025
Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers
Mazyar Shadman, Sairah Ahmed, Michael T Byrne, et al.
Page
of 23